Telix Pharmaceuticals Ltd
TLXHealthcare|Biotechnology|Australia
$11.14
-0.65 (-5.47%)
Upcoming Data Readouts (8)
Nov 2026
Est. completion
Apr 2027
Est. completion
P1Bone Pain
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
NCT07197645n=33
Jul 2027
Est. completion
P3Neoplastic Disease
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
NCT07100730n=50
Aug 2027
Est. completion
P3ccRCC
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
NCT07197580n=40
Oct 2027
Est. completion
P1P2Advanced Cancer
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT05663710n=100
Dec 2027
Est. completion
P3Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345n=520
Dec 2027
Est. completion
P2Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04402151n=50
Dec 2029
Est. completion
P2Clear Cell Renal Cell Carcinoma
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
NCT06447103n=91
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.